Key Points
- Kyle Gano, Neurocrine's CEO, sold 36,400 shares on January 16 at an average price of $132.70 for about $4.83M, cutting his position by 20.59% to 140,407 shares valued at roughly $18.63M.
- The company posted a quarterly EPS beat, reporting $2.17 per share vs. $1.58 consensus and revenue of $794.9M, up 27.8% year-over-year.
- Analysts maintain a consensus rating of "Moderate Buy" with a $175.10 average price target; the stock carries a $13.41B market cap, a P/E of 32.19, and a 52-week range of $84.23–$160.18.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Get Free Report) CEO Kyle Gano sold 36,400 shares of the stock in a transaction dated Friday, January 16th. The shares were sold at an average price of $132.70, for a total value of $4,830,280.00. Following the completion of the sale, the chief executive officer directly owned 140,407 shares in the company, valued at $18,632,008.90. This represents a 20.59% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Kyle Gano also recently made the following trade(s):
- On Tuesday, November 4th, Kyle Gano sold 300 shares of Neurocrine Biosciences stock. The stock was sold at an average price of $141.97, for a total value of $42,591.00.
Neurocrine Biosciences Stock Performance
NBIX stock opened at $134.54 on Wednesday. The company's 50 day moving average price is $144.15 and its 200 day moving average price is $140.11. The firm has a market capitalization of $13.41 billion, a price-to-earnings ratio of 32.19, a PEG ratio of 0.65 and a beta of 0.28. Neurocrine Biosciences, Inc. has a fifty-two week low of $84.23 and a fifty-two week high of $160.18.
Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last issued its quarterly earnings results on Tuesday, October 28th. The company reported $2.17 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.58 by $0.59. Neurocrine Biosciences had a net margin of 15.95% and a return on equity of 15.82%. The company had revenue of $794.90 million during the quarter, compared to the consensus estimate of $746.61 million. During the same quarter in the previous year, the firm earned $1.81 earnings per share. The firm's quarterly revenue was up 27.8% on a year-over-year basis. Equities analysts forecast that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current fiscal year.
Hedge Funds Weigh In On Neurocrine Biosciences
Institutional investors have recently modified their holdings of the business. AlTi Global Inc. raised its stake in shares of Neurocrine Biosciences by 1.0% during the 3rd quarter. AlTi Global Inc. now owns 6,828 shares of the company's stock worth $959,000 after purchasing an additional 70 shares in the last quarter. Vanguard Personalized Indexing Management LLC increased its holdings in Neurocrine Biosciences by 0.7% in the third quarter. Vanguard Personalized Indexing Management LLC now owns 11,112 shares of the company's stock worth $1,560,000 after buying an additional 77 shares during the last quarter. Perigon Wealth Management LLC raised its position in Neurocrine Biosciences by 3.1% during the fourth quarter. Perigon Wealth Management LLC now owns 2,590 shares of the company's stock valued at $367,000 after acquiring an additional 78 shares in the last quarter. Diametric Capital LP lifted its stake in Neurocrine Biosciences by 2.6% in the second quarter. Diametric Capital LP now owns 3,244 shares of the company's stock valued at $408,000 after acquiring an additional 81 shares during the last quarter. Finally, Signaturefd LLC grew its position in Neurocrine Biosciences by 4.5% in the fourth quarter. Signaturefd LLC now owns 1,925 shares of the company's stock worth $273,000 after acquiring an additional 83 shares in the last quarter. 92.59% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
A number of research firms have weighed in on NBIX. Mizuho raised their price target on Neurocrine Biosciences from $146.00 to $175.00 and gave the company a "neutral" rating in a research note on Friday, December 12th. Stifel Nicolaus increased their price objective on Neurocrine Biosciences from $183.00 to $188.00 and gave the company a "buy" rating in a report on Thursday, December 11th. JPMorgan Chase & Co. cut their target price on Neurocrine Biosciences from $179.00 to $177.00 and set an "overweight" rating on the stock in a research report on Monday, January 12th. Citigroup upped their price target on Neurocrine Biosciences from $175.00 to $203.00 and gave the company a "buy" rating in a report on Wednesday, October 29th. Finally, Canaccord Genuity Group increased their price target on shares of Neurocrine Biosciences from $160.00 to $164.00 and gave the company a "buy" rating in a research note on Wednesday, October 29th. Seventeen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $175.10.
View Our Latest Analysis on NBIX
Neurocrine Biosciences Company Profile
(
Get Free Report)
Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine's operations encompass drug discovery, clinical development and commercialization activities.
The company's lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
